Ann Surg Case Rep | Volume 4, Issue 2 | Research Article | Open Access

Breast Cancer Peritoneal Metastasis Role of Cytoreductive Surgery and HIPEC

Spiliotis J^1*, Ntinas A¹, Koustas P¹, Koupanis CH², Stefanopoulou² and Dadoudis G¹

¹4th Department of Surgery and Oncology, European Interbalkan Medical Center, Thessaloniki, Greece
²ICU, European Interbalkan Medical Center, Thessaloniki, Greece

^*Correspondance to: Spiliotis J 

Fulltext PDF

Abstract

Peritoneal metastases from breast cancer are extremely rare. The literature provides no information regarding this infrequent event and its management. We present outcomes in 5 patients (mean age 53 years) with peritoneal metastasis from breast cancer without evidence of liver, bone or lung deposits. Patients were treated with Cytoreductive Surgery (CRS) plus HIPEC by the closed technique at 42.5% for 60 min with cisplatin 100 mg/m2 and paclitaxel 175 mg/m2. Histology of the primary breast cancer was ductal carcinoma in two of them while in the rest three was lobular carcinoma. Mean Peritoneal Cancer Index (PCI) was 16. In 50% of cases complete cytoreduction was achieved. One patient died of the disease at 54 months and four are alive and disease free at 68, 78, 12 and 10 months respectively. These results encouraging

Keywords:

Breast cancer; Peritoneal metastasis; Cytoreductive oncology; CRS; HIPEC

Citation:

Spiliotis J, Ntinas A, Koustas P, Koupanis CH, Stefanopoulou, Dadoudis G. Breast Cancer Peritoneal Metastasis Role of Cytoreductive Surgery and HIPEC. Ann Surg Case Rep. 2021; 4(2): 1047..